Research shows that biomarkers of Alzheimer’s disease vary across ethnic groups, increasing the risk of misdiagnosis and challenging medical practice.
A new study challenges the one-size-fits-all model of Alzheimer’s diagnosis. Researchers at the University of Southern California (USC) found that the biological precursors of dementia differ significantly depending on ethnicity. To date, research has largely been based on data from people of European descent.
The results, published in the Alzheimer’s Association journal, show different distribution patterns of harmful proteins in the brain. The processes are different for black and Hispanic people than for white people. These findings could have far-reaching consequences for global neurological practice.
Advertisement
Since research shows how dementia risks vary from person to person, early awareness of one’s own memory is crucial. The anonymous 7-question self-test offers you an initial assessment of possible warning signs in just two minutes. Start the free dementia self-test here
A turning point for brain research
Table of Contents
The team analyzed brain scans and memory tests from over 1,500 older adults. The participants did not yet show any symptoms of dementia. Using state-of-the-art PET scans, the researchers made protein accumulations visible long before external symptoms appeared.
They focused on two proteins: amyloid beta and tau. The analysis showed that black and Hispanic study participants had significantly higher tau levels in memory-related brain regions. Remarkable: This increased concentration occurred before the massive formation of amyloid plaques.
Traditionally, amyloid is considered to be the first cause of the disease. The data now suggests a varying biological timeline. Established biomarkers therefore do not have the same predictive power for all people.
Blood tests pose a risk of misdiagnosis
In addition to complex brain scans, the focus is on cost-effective blood tests. The protein p-tau217 is considered a promising marker. But here too, current data shows massive ethnic fluctuations.
In a study with almost 2,800 participants, p-tau217 levels in the blood were lower in black and Hispanic adults. Paradoxically, these same groups had a higher prevalence of cognitive impairment.
Another study from Washington University in St. Louis supports these concerns. Three of four experimental Alzheimer’s blood tests gave significantly different results in black people. Experts strongly warn of a disproportionately high risk of misdiagnosis.
Advertisement
Given the complexity of blood tests and the risk of misdiagnosis, it is important to be able to correctly classify your own laboratory findings. This 25-page guide clearly explains which values really count and how you can better monitor your health. Free report: interpret laboratory values correctly
What’s behind the differences?
The reasons for the biological differences are complex. Genetic factors only provide part of the explanation. The risk gene variant APOE4 has a significantly weaker effect in black people.
Rather, the focus is on comorbidities and social factors. In the Washington University cohort, 67 percent of black participants had high blood pressure, compared to 45 percent of white participants. For diabetes there was a difference of 28 to 5 percent.
Since such diseases are closely linked to the risk of dementia, they probably also influence biomarker tests. Environmental factors such as air quality, education levels and access to medical care also play a significant role.
The pharmaceutical industry needs to rethink
The findings represent a fundamental turning point for medical practice and the research-based pharmaceutical industry. The historical underrepresentation of minorities in clinical trials has resulted in a distorted picture.
Diagnostics developers are now forced to recalibrate their reference values. Leading researchers are calling for population-specific limits for biomarkers. This is particularly critical as new antibody therapies enter the market. Their effectiveness depends heavily on an extremely early, biologically correct diagnosis.
Misdiagnosis would not only cause human suffering, but would also result in enormous costs if expensive drugs were prescribed to the wrong patient groups.
Where is research heading?
Neurological research will have to change significantly in the coming years. The scientific community is planning much larger, multicenter studies. The goal: to evaluate the ethnic differences in biomarkers in even more detail.
American and international research institutes want to dramatically increase the diversity of study participants. At the same time, the exact mechanisms behind the aberrant protein deposits should be deciphered.
For patients, this means hope for fairer and more accurate diagnostic procedures in the medium term. Until then, experts urge caution when interpreting standard tests in patients who are not of European descent.
Get the knowledge advantage of the stock professionals now.
Get the knowledge advantage of the stock professionals now.“/>
Since 2005, the trading notes newsletter has been delivering reliable stock recommendations – three times a week, directly to your inbox. 100% free. 100% expert knowledge. Simply enter your email address and from today on you won’t miss any top opportunities. Subscribe now.
For. Always. For free.
